Current Trends in Targeted Therapies for Glioblastoma Multiforme

Ohka, Fumiharu; Natsume, Atsushi; Wakabayashi, Toshihiko

doi:10.1155/2012/878425

Cited by 151 publications

(132 citation statements)

References 104 publications

Supporting

Mentioning

130

Contrasting

Unclassified

Order By: Relevance

“…The need for precise and safe targeted cell delivery and the lack of effective drugs to eradicate GSCs has revealed this as a challenging objective. Further, the presence of the tight cerebrovascular barrier hampers the passage of large macromolecules to target the brain tumor cells [11].…”

Section: Introductionmentioning

confidence: 99%

A combined microRNA-based targeted therapeutic approach to eradicate glioblastoma stem-like cells

Esposito

Nuzzo

Kumar

et al. 2016

Journal of Controlled Release

View full text Add to dashboard Cite

Release, 238 . pp. 43 57. ISSN 0168 3659 It is advisable to refer to the publisher's version if you intend to cite from the work.http://dx.doi.org/10. 1016/j.jconrel.2016.07.032 For more information about UCLan's research in this area go to http://www.uclan.ac.uk/researchgroups/ and search for . This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT

show abstract

Section: Introductionmentioning

confidence: 99%

A combined microRNA-based targeted therapeutic approach to eradicate glioblastoma stem-like cells

Esposito

Nuzzo

Kumar

et al. 2016

Journal of Controlled Release

View full text Add to dashboard Cite

show abstract

“…The synergism between HLF and TMZ could be used in treating tumors with unmethylated O 6 -methylguanine-DNA methyltransferase (MGMT) that shows a drug-resistant phenotype. 10,20 To further test the long-term efficacy of HLF and TMZ in vivo, we treated CD1 nude mice carrying an orthotopic GBM xenograft with TMZ alone and with HLF. Mice with combined treatment survived 10 days longer than those treated with TMZ alone.…”

mentioning

confidence: 99%

In vitro and in vivo effect of human lactoferrin on glioblastoma growth

Arcella

Oliva

Staffieri

et al. 2015

JNS

View full text Add to dashboard Cite

Documented studies have shown that HLF also significantly reduces the development of various neoplasms such as esophageal, lung, bladder, and colon cancer. 9,28 InterestabbreviatioNs bLF = bovine lactoferrin; BrdU = bromodeoxyuridine; BSA = bovine serum albumin; DMEM = Dulbecco's modified Eagle's medium; FACS = fluorescence-activated cell sorting; FCS = fetal calf serum; FRFSE = fast-recovery fast spin-echo; GBM = glioblastoma; HLF = human lactoferrin; NK = natural killer; PBS = phosphate-buffered saline; TMZ = temozolomide. , and 100 mg/ml, and 1 mg/ml) and in combination with TMZ. In in vivo experiments they assessed tumor size reduction in CD1 nude mice carrying an orthotopic GBM xenograft and orally treated with HLF. results Lactoferrin causes growth inhibition in the NMD and FN primary cell lines and in the U87MG continuous cell line. This inhibition seemed to be modulated by the downregulation of cyclin D1 and D4. Western blot and fluorescenceactivated cell sorting analysis showed inhibition of the cell cycle in G0/G1 and G2 phases. When administered in nude mice, HLF (60 mg/kg/day) decreased tumor size about 30%, as shown in both histological analyses and high-field brain MRI. Administration of HLF with TMZ enhanced the effect of chemotherapy both in vitro and in vivo. coNclusioNs This study demonstrated that HLF can inhibit GBM cell growth, suggesting that this nontoxic substance may have a role in potentiating the effect of current TMZ treatment of GBM.

show abstract

“…First, molecularly targeted agents with demonstrated therapeutic benefits in other types of cancer have shown minimal or no efficacy against GBM (5). For example, bevacizumab, a neutralizing antibody against vascular endothelial growth factor, is effective in treating certain cancers, including metastatic colon cancer and non-small cell lung cancer (NSCLC).…”

Section: Introductionmentioning

confidence: 99%

Repurposing antipsychotics as glioblastoma therapeutics: Potentials and challenges

2016

View full text Add to dashboard Cite

Abstract. Glioblastoma multiforme (GBM) is the most common and most lethal primary brain tumor, with tragically little therapeutic progress over the last 30 years. Surgery provides a modest benefit, and GBM cells are resistant to radiation and chemotherapy. Despite significant development of the molecularly targeting strategies, the clinical outcome of GBM patients remains dismal. The challenges inherent in developing effective GBM treatments have become increasingly clear, and include resistance to standard treatments, the blood-brain barrier, resistance of GBM stem-like cells, and the genetic complexity and molecular adaptability of GBM. Recent studies have collectively suggested that certain antipsychotics harbor antitumor effects and have potential utilities as anti-GBM therapeutics. In the present review, the anti-tumorigenic effects and putative mechanisms of antipsychotics, and the challenges for the potential use of antipsychotic drugs as anti-GBM therapeutics are reviewed.

show abstract

Current Trends in Targeted Therapies for Glioblastoma Multiforme

Cited by 151 publications

References 104 publications

A combined microRNA-based targeted therapeutic approach to eradicate glioblastoma stem-like cells

A combined microRNA-based targeted therapeutic approach to eradicate glioblastoma stem-like cells

In vitro and in vivo effect of human lactoferrin on glioblastoma growth

Repurposing antipsychotics as glioblastoma therapeutics: Potentials and challenges

Contact Info

Product

Resources

About